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Preemptive use of etodolac on tooth 
sensitivity after in-office bleaching: a 
randomized clinical trial
Purpose: This study determined the effectiveness of the preemptive 
administration of etodolac on risk and intensity of tooth sensitivity and 
the bleaching effect caused by in-office bleaching using 35% hydrogen 
peroxide. Material and methods: Fifty patients were selected for this triple-
blind, randomized, crossover, and placebo-controlled clinical trial. Etodolac 
(400 mg) or placebo was administrated in a single-dose 1 hour prior to the 
bleaching procedure. The whitening treatment with 35% hydrogen peroxide 
was carried out in two sessions with a 7-day interval. Tooth sensitivity was 
assessed before, during, and 24 hours after the procedure using the analog 
visual scale and the verbal rating scale. Color alteration was assessed by a 
bleach guide scale, 7 days after each session. Relative risk of sensitivity was 
calculated and adjusted by session, while overall risk was compared by the 
McNemar’s test. Data on the sensitivity level of both scales and color shade 
were subjected to Friedman, Wilcoxon, and Mann-Whitney tests, respectively 
(α=0.05). Results: The preemptive administration of etodolac did not affect 
the risk of tooth sensitivity and the level of sensitivity reported, regardless of 
the time of evaluation and scale used. The sequence of treatment allocation 
did not affect bleaching effectiveness, while the second session resulted in 
additional color modification. The preemptive administration of etodolac in 
a single dose 1 hour prior to in-office tooth bleaching did not alter tooth 
color, and the risk and intensity of tooth sensitivity reported by patients. 
Conclusion: A single-dose preemptive administration of 400 mg of etodolac 
did not affect either risk of tooth sensitivity or level of sensitivity reported 
by patients, during or after the in-office tooth bleaching procedure.
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Introduction
Tooth whitening is a simple and non-invasive 
treatment commonly carried out to reestablish smile 
aesthetics. High success rates have been demonstrated 
for bleaching techniques applying 35% hydrogen 
peroxide (HP35%)2. Hydrogen peroxide (H2O2)-based 
bleaching agents at high concentrations (typically 15-
38%) are currently used for in-office techniques due 
to their high oxidizing ability12,25. However, the low 
molecular weight of H2O2 allows its penetration across 
the entire dentin tissue, reaching the pulp chamber 
and promoting damage of pulp stem cells, which is 
reported by patients as tooth sensitivity15,29.
Prior clinical trials have reported absolute risk of tooth 
sensitivity as high as 95% when highly concentrated 
H2O2 is used for in-office tooth bleaching9,20,23,25. Thus, 
the preemptive use of desensitizer agents3,30 or anti-
inflammatories7,22,23,27 has been proposed to reduce the 
risk of post-bleaching tooth sensitivity. Only the former 
significantly decreased tooth sensitivity; however, the 
application of desensitizers, when not incorporated into 
the bleaching gel, adds an extra step to the bleaching 
protocol, which is contrary to a clinician’s need for 
simplification. On the other hand, the preemptive use 
of anti-inflammatories does not increase the number 
of steps in the bleaching protocol. Unfortunately, 
prior studies evaluating etoricoxib, ibuprofen, or 
dexamethasone were unable to demonstrate any 
beneficial effect on tooth sensitivity caused by tooth 
bleaching7,13,22,23,28.
Etoricoxib and ibuprofen are grouped as class 
II drugs by the Biopharmaceutical Classification 
System (BCS), presenting low solubility and high 
permeability, which can hinder their absorption and 
create bioavailability mismatch during the bleaching 
procedure28. Moreover, anti-inflammatory drugs may 
have a specific action over inflammatory mediators 
(bradykinin) and the neurotransmitter (substance 
P) of tooth pain caused by dental bleaching6. Among 
non-steroid anti-inflammatory drugs (NSAIDs), 
etodolac demonstrated efficacy on the control of 
prostaglandins and bradykinins18. Nevertheless, there 
is no clinical evidence regarding the use of etodolac on 
the reduction of tooth sensitivity caused by in-office 
bleaching.
Thus, this study aimed to evaluate the effectiveness 
of the preemptive prescription of etodolac on risk of 
tooth sensitivity during and after in-office bleaching 
treatment. The first hypothesis evaluated was that 
etodolac would reduce both level and risk of tooth 
sensitivity when administrated in a single dose prior 
to in-office bleaching. The second hypothesis tested 
was whether the use of etodolac would reduce tooth 
sensitivity with no effect on tooth bleaching.
Material and methods 
This cl inical tr ial fol lowed the CONSORT 
statements and was approved by the Scientific 
Review Committee and by the Committee for the 
Protection of Human Subjects of the local university 
(CAAE 37578714.4.0000.5546), and registered at 
clinicaltrials.gov under the number NCT02881619.
Trial design
This study was a randomized, triple-blind, placebo-
controlled clinical trial with a crossover design. Patients 
included signed an informed consent form and were 
submitted to two in-office bleaching sessions receiving 
placebo (control) or etodolac prior to the bleaching 
procedure, while different treatments were allocated 
for each session.
A one-week interval (“washout”) in-between 
sessions was established. The study was conducted 
at the clinic of the School of Dentistry of the local 
university from November 2014 to July 2015.
Participants
Patients from 18 to 35 years old with good oral 
health were included in this clinical trial. From the 
patients who received placebo/etodolac, 6 were men 
and 19 were women, and for etodolac/placebo, 12 
were men and 13 were women; the average age was 
23 years; 64% were women.
Patients with any of the six upper anterior teeth with 
caries, restoration, severe discoloration (e.g., stains 
caused by tetracycline), enamel hypoplasia, gingival 
recession, dentin exposure, pulpitis, or endodontics 
were excluded, as well as smokers. Participants 
submitted to previous bleaching procedures, with prior 
tooth sensitivity, known allergy to any component 
of the medication used in the study, and pregnant 
or breastfeeding women were also excluded. An air 
stream was applied to teeth to verify the presence or 
absence of sensitivity (none or zero). Only patients 
presenting all six upper anterior teeth with shade 
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mismatch of 2.5 M2 (Vita Bleach guide 3D-Master 
scale, Vita-Zahnfabrik, Bad Sackingen, Germany) 
– A3.5 Vita Classical equivalence – or darker were 
included.
Sample size calculation
The sample calculation was based on the primary 
binary outcome (sensitivity risk 24 hours after the 
procedure) for superiority trial. The power of the test 
was set at 80%, considering a type I error of 0.05 
and risk of tooth sensitivity of 90%, based on a prior 
study using a similar bleaching agent23; moreover, a 
reduction around 30% was expected after treatment. 
The calculation resulted in fifty patients.
Randomization
A randomized list was computer-generated by a 
person not involved in intervention or evaluation. 
Participants were defined as blocks in the randomization 
process, in which the sequence of treatment (placebo 
or etodolac) was randomly set for each block by 
computer-generated tables (www.sealedenvelope.
com). The sequence was inserted into sealed 
envelopes numbered from 1 to 50 that were opened 
by the operator only at the moment of intervention. 
Patients were numbered according to the sequence of 
enrollment. Neither the participant nor the operator 
knew the group allocation, determining a blinded 
protocol.
Baseline evaluation
Prior to the bleaching procedure, teeth were 
cleaned using rubber cups associated with pumice 
and water. The shades of upper incisors and canine 
teeth (13, 12, 11, 21, 22, and 23) were assessed on 
a baseline using the bleach guide scale. Color was 
analyzed by two previously calibrated evaluators. 
Both evaluators presented superior color matching 
competency according to the ISO (International 
Organization for Standardization)/TR 28642:2011. 
Shade tabs selected were converted to scores ranging 
from 1 (whiter shade – 0M1) to 15 (darker shade – 
5M3).
Considering a possible effect of dental anxiety 
on the sensitivity reported by patients, the Corah’s 
Dental Anxiety Scale was used to determine the level 
of anxiety of each patient related to the procedure17. 
Each answer to the survey instrument was scored on 
a scale from 1 to 5 (four questions) and the sum of 
scores was used to determine the level of anxiety: low 
was under 12, moderate was between 12 and 14, and 
high was over 14.
Intervention
One hour before each bleaching session and right 
after the prophylaxis, patients received a capsule 
containing 400 mg of NAISE etodolac (Flancox™, 
Apsen Farmaceutica S/A) or 400 mg of placebo (inert 
content) according to randomization. Capsules had the 
same appearance and were manufactured by a person 
not involved in intervention or evaluation. They were 
placed into two bottles identified by letters according 
to the treatment. Neither the operators responsible 
for intervention and evaluation nor the patients knew 
the content of each capsule.
The color evaluation was verified, and the light-
cured resin dam was applied (Top Dam, FGM, Joinville, 
SC, Brazil) and polymerized (Radii-cal, SDI, Bayswater, 
Australia) on the gingival tissue corresponding to the 
teeth to be bleached. A 35% hydrogen peroxide-based 
bleaching agent (Whiteness HP Blue, FGM, Joinville, 
SC, Brazil) was mixed and applied to the buccal surface 
of teeth for 40 minutes. After that, the bleaching agent 
was removed. A second session was carried out after 
a week following the same procedures. At this time, 
the patient received a single-dose capsule containing 
etodolac or placebo (different from the ones received 
at the first session), one hour before the procedure. 
During the bleaching treatment, patients were advised 
not to ingest colored food and beverages.
Evaluations
Tooth sensitivity reported by patients was assessed 
using a visual analog scale (VAS) and a verbal rating 
scale (VRS). The VAS consisted of a 10-cm long 
scale ranging from green (absence of pain) to red 
(unbearable pain). Patients set their level of sensitivity 
by pointing to the color corresponding to the pain 
level, while the distance from this point to the green 
border was recorded. For the VRS, patients reported 
their level of sensitivity based on scores: 0= none; 1= 
mild; 2= moderate; 3= considerable; and 4= severe. 
Tooth sensitivity was assessed during bleaching, 
immediately after removing the bleaching agent, and 
after 24 hours. For this last assessment, only the 
VRS was used due to the difficulty of patients to fill 
the VAS at home. One week after each session, tooth 
color was evaluated again using the same procedure 
described previously.
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Statistical analysis
Demographic data from patients were analyzed 
to determine age, gender, and anxiety level for each 
allocation sequence. Comparisons among allocation 
sequences were performed by Mann-Whitney (age), 
Fisher’s exact (gender), and chi-square (anxiety level) 
tests.
Based on the presence of any tooth sensitivity 
(VRS scores different from 0), the absolute risk, odds 
ratio, and relative risk were calculated regarding the 
treatments for each moment of bleaching evaluation/
session, as well as the confidence intervals (95%). For 
each moment, differences on presence/absence ratios 
were analyzed by Fisher’s exact test. For the overall 
risk related to each treatment, odds ratio was adjusted 
to the independent variable of “session of bleaching” 
using Mantel-Haenszel statistics. The homogeneity of 
odds ratios was analyzed by Breslow-Day and Tarone’s 
tests. Next, the estimated odds ratio was converted to 
relative risk and the overall presence/absence ratios 
were analyzed by the McNemar’s test, considering the 
study design (crossover).
For the VRS, data from scores observed at 
each moment of bleaching evaluation/session were 
submitted to the Mann-Whitney rank sum test. Despite 
the measurement of tooth sensitivity using the VAS, 
which provided a continuous outcome, data assessed 
with this scale did not show normal distribution 
(Shapiro-Wilk’s test). Thus, data from the VAS were 
also analyzed by the Mann-Whitney rank sum test, 
performing one test per time of evaluation.
For color evaluation, comparisons among sequences 
of treatment were performed using the Mann-Whitney 
rank sum test. Friedman test followed by Dunn’s post 
hoc test were used to analyze the difference between 
the moments of evaluation for each sequence of 
treatment. All statistical analyses were performed 
adjusting the initial significance level (α=0.05) by the 
Bonferroni correction.
Results
Figure 1 shows the flow chart of patients assessed 
for eligibility, who were included in the study 
and analyzed. Table 1 shows the demographic 
characteristics of patients allocated for each sequence 
of treatment. Regarding anxiety, 88% of patients had 
a low level and only 2% had a high level (p=0.236). 
There was no difference among the sequences of 
treatment for any demographic characteristic analyzed 
(age: p=0.089 and gender: p=0.140).
Table 2 shows the results of tooth sensitivity risk. 
The treatment that patients received prior to the 
Figure 1- Flow chart of patients
Preemptive use of etodolac on tooth sensitivity after in-office bleaching: a randomized clinical trial
J Appl Oral Sci. 2018;26:e201604735/9
Age (years) Median
(1st / 3rd quartiles)
p-value
Total 23.0  (21.0/26.0)
Placebo/Edotolac 23.8 (21.0/25.5) p* = 0.089
Edotolac/Placebo 25.0 (22.0/28.0)
Gender Total n (%)
Male 18 (36.0%)
Female 32 (64.0%)
Placebo/Edotolac p** = 0.140
Male 6 (24.0%)
Female 19 (76.0%)
Edotolac/Placebo
Male 12 (52.0%)
Female 13 (48.0 %)
Level of anxiety Total n (%)
Low anxiety 44 (88.0%)
Moderate anxiety 5 (10.0%)
High anxiety 1 (2.0%)
Placebo/Edotolac p*** = 0.236
Low anxiety 21 (84.0%)
Moderate anxiety 4 (16.0%)
High anxiety 0 (0.0%)
Edotolac/Placebo
Low anxiety 23 (92.0%)
Moderate anxiety 1 (4.0%)
High anxiety 1 (4.0%)
* Mann-Whitney rank sum test; ** Fisher Exact test; *** Chi-square test.
Table 1- Profile of patients included in the study allocated to each sequence of treatment
Session Moment of evaluation During Immediately 
after
24 h after
Treatment Edotolac Placebo Edotolac Placebo Edotolac Placebo
1st session Presence of sensitivity (yes/no) (10/15) (11/14) (9/16) (10/15) (3/22) (2/23)
Odds ratio (95% CI) 0.52
(0.17 – 1.61)
0.84
(0.27 – 2.65)
1.57
(0.24 – 10.30)
Relative risk (95% CI) 0.71
(0.40 – 1.29)
0.90
(0.44 – 1.83)
1.50
(0.27 – 8.22)
p-value* 0.396 1.000 1.000
2nd session Presence of sensitivity (yes/no) (8/17) (5/20) (6/19) (4/21) (1/24) (1/24)
Odds ratio (95% CI) 1.88
(0.52 – 6.85)
1.66
(0.41 – 6.79)
1.00
(0.59 – 16.93)
Relative risk (95% CI) 1.60
(0.61 – 4.22)
1.50
(0.48 – 4.68) 
1.00
(0.06 – 15.12)
p-value* 0.520 0.725 1.000
Average Odds ratio (95% CI)** 0.92
(0.40 – 2.09)
1.11
(0.46 – 2.67)
1.37
(0.29 – 6.51)
Relative risk*** 0.95 1.08 1.34
p-value**** 1.000 1.000 0.683
* Fisher exact test; **  Mantel-Haenszel common odds ratio estimate;  *** Based on odds ratio estimated; ****McNemar's test. The cut-off 
value of type I error (α=0.0056) was adjusted by Bonferroni correction.
Table 2- Results of risk of tooth sensitivity observed for each treatment
Preemptive use of etodolac on tooth sensitivity after in-office bleaching: a randomized clinical trial
J Appl Oral Sci. 2018;26:e201604736/9
bleaching procedure did not affect the risk to sensitivity 
at any of the moments of evaluation (during and 
immediately after: p=1.0; after 24 hours: p=0.683). 
Figure 2 shows the results for level of sensitivity 
assessed by the VRS. Treatment did not affect level 
of sensitivity, regardless of the moment of evaluation. 
Figure 2 - Scores of tooth sensitivity from the VRS (0 to 4)
Figure 3- Level of tooth sensitivity assessed with VAS (cm)
Preemptive use of etodolac on tooth sensitivity after in-office bleaching: a randomized clinical trial
J Appl Oral Sci. 2018;26:e201604737/9
Similar results were observed when the VAS was used 
(Figure 3).
In regards to bleaching effectiveness, the bleaching 
procedure carried out in this study was able to 
significantly reduce the shade scores from the bleach 
guide, while the second session resulted in additional 
bleaching effect (Figure 4). The sequence of treatment 
did not affect bleaching effectiveness.
Discussion
Tooth bleaching performed by patients at home 
using low-concentration peroxides has been reported 
as the first-choice technique for vital bleaching, and 
probably the most widely used one5,11. However, 
procedures using high-concentration bleaching agents 
applied in office by clinicians remain an important 
protocol used to bleach discolored teeth for specific 
indications of tooth bleaching. This protocol is 
separate and intended to aid patients who cannot 
adapt to the use of home-based bleaching trays and 
who have contraindications related to the gastric 
system, because it reduces the risk of gel intake14, 
and to control the risk factor for developing gingival 
irritation10. In-office bleaching is also indicated to 
patients requiring faster results, while this technique 
can be combined with at-home bleaching26.
In-office techniques have demonstrated high 
bleaching effectiveness using high-concentration 
hydrogen peroxides26. However, high-concentrated 
bleaching agents also result in increased tooth 
sensitivity reported by patients during and up to 24 
hours after the bleaching procedure, which is the main 
adverse effect related to in-office tooth bleaching9,20,21. 
Even though tooth sensitivity is related to the 
inflammatory process of pulp tissue20, the findings of 
this study showed that the preemptive use of etodolac 
in a single dose did not affect the risk and level of 
tooth sensitivity caused by in-office bleaching. As 
expected, preemptive administration of etodolac also 
did not affect the bleaching results. Thus, the first 
hypothesis of the study was rejected and the second 
one was accepted.
Unlike the tooth sensitivity typically reported by 
patients presenting teeth with dentin exposure, which 
relates mainly to thermal stimuli, bleached teeth can 
hurt even in the absence of any stimulus, showing that 
the pain mechanism related to peroxides is different 
from other types of tooth pain20. Moreover, the 
sensitivity caused by tooth bleaching tends to increase 
within a few hours following the bleaching procedure, 
when most patients described the pain as a “twinge” 
or “shock-like.” It has been demonstrated that the 
oxidizing agents used during the bleaching procedure 
cause a reduction on metabolism, viability, and cell 
proliferation20, allowing to increase the expression 
of inflammatory mediators, such as substance P and 
bradykinin, which is a vasoactive peptide released by 
nerves resulting in a neurogenic inflammation6. Thus, a 
Figure 4- Scores from the bleach guide scale
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preemptive administration of anti-inflammatories could 
be a reasonable approach to reduce tooth sensitivity 
associated with bleaching procedures. However, in 
this study, sensitivity was not lower during and 24 
hours after the bleaching procedure. Unfortunately, 
the peak of tooth sensitivity was not measured in this 
study, even though this outcome could allow to assess 
a possible effect of etodolac on sensitivity following 
the end of the bleaching procedure.
A prior study demonstrated that etodolac presents 
higher effectiveness on bradykinin inhibition than other 
drugs commonly used to control the inflammatory 
process, motivating its use in this study18. Regarding 
pharmacokinetics, etodolac reaches its maximal 
plasma concentration around 1 to 2 hours after its 
administration4. Thus, it was expected that maximal 
plasma concentration would be reached during the 
bleaching procedure. Unfortunately, no effect of 
the preemptive administration of etodolac on the 
reported tooth sensitivity was observed at this time of 
evaluation for both sessions. Despite its demonstrated 
efficacy on inflammation control, the analgesic effect of 
etodolac increases when its administration is repeated, 
whereas a single dose prior to the bleaching procedure 
seems insufficient to prevent tooth sensitivity19.
Another important observation regarding 
pharmacokinetics is that a crossover design was used 
in this study with a 1-week interval period. Considering 
that the half-life of etodolac after oral administration 
is around 13 hours16, it is expected to find no residual 
effect after 1-week. Moreover, the crossover design 
avoids bias related to pain thresholds of patients1.
Participants included in this study were 
predominantly young females presenting low level 
of anxiety. All these demographics characteristics 
of the studied population might be associated with 
differences in pain thresholds. Higher tooth sensory 
threshold has been demonstrated in males due to 
differences in crown diameters of teeth and underlying 
mechanisms such as neurological differences or 
behavior aspects8. Regarding the age of participants, 
a recent review did not find any relation between age 
and the risk to or level of tooth sensitivity27. However, 
it is important to emphasize that most participants 
from trials included in that review were under 30 
years old27. Another important demographic aspect 
assessed in this study was the participants’ level of 
dental anxiety prior to bleaching procedures. It has 
been demonstrated that dental anxiety is a strong 
predictor of pain and that anxious participants are 
prone to develop painful responses24. In this research, 
almost 90% of participants presented low anxiety 
prior to bleaching procedures, which can be justified 
by the low invasive aspect of intervention, despite 
the patients’ concern about tooth sensitivity. In fact, 
despite 66% of participants reporting various level 
of tooth sensitivity (high risk), the actual level of 
sensitivity reported was low (medians below moderate 
at VRS, and means lower than 2 at VAS).
In addition to the evaluation of tooth sensitivity, 
we also assessed color alteration promoted by 
bleaching procedures. The data analysis of color 
evaluation used the sequence of allocation instead 
of the treatment (placebo or etodolac). If we had 
used treatment, different participants between the 
first and second sessions would be compared for the 
same treatment, which would have impaired correct 
color changes assessment. Moreover, the main aim of 
color evaluation was to show the effectiveness of the 
bleaching technique used.
In our study, the protocol that was carried out 
resulted in significant bleaching effect, while an 
additional color alteration was achieved at the second 
session. In addition, the last color evaluation was 
performed a week after the last bleaching session 
of this study, while longer times may be required 
for color stabilization21. However, a shorter time 
was used because the tooth sensitivity reported by 
patients was the main outcome of this trial. It has 
been demonstrated that two sessions of in-office 
tooth bleaching results in a mean change of 5.3 (± 
2.8) units on shade guides26, which is similar to the 
average color change achieved in this research. Factors 
such as patient’s age and color at baseline have been 
strongly associated with bleaching effectiveness, 
while young patients and darker teeth show more 
pronounced color changes27. We found no difference 
in baseline regarding these parameters between the 
sequence of allocation, while the inclusion of young 
participants presenting all teeth darker than 2.5 M2 
(score 7) favored obtaining significant color bleaching.
In conclusion, the preemptive administration of 
etodolac in a single dose 1 hour prior to the bleaching 
procedure was unable to reduce both risk and level of 
sensitivity caused by in-office bleaching. A limitation 
of this study was that the preemptive treatment was 
administrated only for a young population (average 
age of 23 years), with prevalence of female patients, 
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while different results can be observed for other 
demographic profiles27.
Conclusions
The preemptive administration of a single dose 
of etodolac previously to the two bleaching sessions 
with 35% hydrogen peroxide did not affect tooth color 
change, risk of sensitivity and level of pain reported by 
the patients (during the sessions, immediately after, 
and 24 h after sessions).
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